Terms: = Breast cancer AND IHC4
53 results:
1. A retrospective validation of CanAssist breast in European early-stage breast cancer patient cohort.
Gunda A; Basavaraj C; Serkad V CP; Adinarayan M; Kolli R; Siraganahalli Eshwaraiah M; Saura C; Ruiz F; Gomez P; Peg V; Jimenez J; Sprung S; Fiegl H; Brunner C; Egle D; Bhattacharyya GS; Bakre MM
Breast; 2022 Jun; 63():1-8. PubMed ID: 35245746
[TBL] [Abstract] [Full Text] [Related]
2. Stratification of Prognosis by Biological Features Following Neoadjuvant Chemotherapy in Luminal breast cancer.
Yamamoto S; Chishima T; Shibata Y; Inoue S; Harada F; Takeuchi H; Yamada A; Narui K; Endo I
In Vivo; 2022; 36(2):859-864. PubMed ID: 35241543
[TBL] [Abstract] [Full Text] [Related]
3. Comparison of Different Molecular Subtypes with 14% Ki-67 Cut-off Threshold in breast cancer Patients of Pakistan- An Indication of Poor Prognosis.
Mushtaq M; Chaudry SS; Khalid Sheikh A; Khan N; Khattak A; Akbar A; Tanwani AK; Khaliq T; Malik MFA; Riaz SK
Arch Iran Med; 2021 Nov; 24(11):837-844. PubMed ID: 34841829
[TBL] [Abstract] [Full Text] [Related]
4. Magnetic resonance imaging radiomics signatures for predicting endocrine resistance in hormone receptor-positive non-metastatic breast cancer.
Yang Y; Li J; Liu Y; Zhong Y; Ren W; Tan Y; He Z; Li C; Ouyang J; Hu Q; Yu Y; Yao H
Breast; 2021 Dec; 60():90-97. PubMed ID: 34536884
[TBL] [Abstract] [Full Text] [Related]
5. Impact of breast cancer risk factors on clinically relevant prognostic biomarkers for primary breast cancer.
Abubakar M; Guo C; Koka H; Zhu B; Deng J; Hu N; Zhou B; Garcia-Closas M; Lu N; Yang XR
Breast Cancer Res Treat; 2021 Sep; 189(2):483-495. PubMed ID: 34185195
[TBL] [Abstract] [Full Text] [Related]
6. Tumor-Associated Stromal Cellular Density as a Predictor of Recurrence and Mortality in breast cancer: Results from Ethnically Diverse Study Populations.
Abubakar M; Zhang J; Ahearn TU; Koka H; Guo C; Lawrence SM; Mutreja K; Figueroa JD; Ying J; Lissowska J; Lyu N; Garcia-Closas M; Yang XR
Cancer Epidemiol Biomarkers Prev; 2021 Jul; 30(7):1397-1407. PubMed ID: 33952648
[TBL] [Abstract] [Full Text] [Related]
7. The ihc4+C score: an affordable and reproducible non-molecular decision-aid in hormone receptor-positive breast cancer. Does it still hold value for patients in 2020?
Harel N; Cheema S; Williams D; Ireland-Jenkin K; Fancourt T; Dodson A; Yeo B
Asia Pac J Clin Oncol; 2021 Aug; 17(4):368-376. PubMed ID: 33567144
[TBL] [Abstract] [Full Text] [Related]
8. Prognostic Value of Modified ihc4 Score in Patients with Estrogen Receptor-Positive Metastatic breast cancer.
Jin L; Chen K; Tan C; Li J; Luo J; Yang Y; Li Y; Li S; Zhu L; Hu Y; Liu F; You Q; Peng M; Jiang Z; Liu Q
Oncologist; 2020 Aug; 25(8):e1170-e1180. PubMed ID: 32476192
[TBL] [Abstract] [Full Text] [Related]
9. Gene Expression Assay in the Management of Early breast cancer.
Caputo R; Cianniello D; Giordano A; Piezzo M; Riemma M; Trovò M; Berretta M; De Laurentiis M
Curr Med Chem; 2020; 27(17):2826-2839. PubMed ID: 31804159
[TBL] [Abstract] [Full Text] [Related]
10. Clinical Validation of BCT Scores With Prognostic Factors in Hormone Receptor-positive, HER2-negative Early breast cancer.
Lee J; Kim WH; Jung JH; Kim WW; Park CS; Lee RK; Park JY; Chae YS; Lee SJ; Kim HJ; Park JY; Park HY
In Vivo; 2019; 33(6):2133-2139. PubMed ID: 31662548
[TBL] [Abstract] [Full Text] [Related]
11. Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer: a systematic review and economic analysis.
Harnan S; Tappenden P; Cooper K; Stevens J; Bessey A; Rafia R; Ward S; Wong R; Stein RC; Brown J
Health Technol Assess; 2019 Jun; 23(30):1-328. PubMed ID: 31264581
[TBL] [Abstract] [Full Text] [Related]
12. Combined quantitative measures of ER, PR, HER2, and KI67 provide more prognostic information than categorical combinations in luminal breast cancer.
Abubakar M; Figueroa J; Ali HR; Blows F; Lissowska J; Caldas C; Easton DF; Sherman ME; Garcia-Closas M; Dowsett M; Pharoah PD
Mod Pathol; 2019 Sep; 32(9):1244-1256. PubMed ID: 30976105
[TBL] [Abstract] [Full Text] [Related]
13. Clinical validation of an immunohistochemistry-based CanAssist-breast test for distant recurrence prediction in hormone receptor-positive breast cancer patients.
Bakre MM; Ramkumar C; Attuluri AK; Basavaraj C; Prakash C; Buturovic L; Madhav L; Naidu N; R P; Somashekhar SP; Gupta S; Doval DC; Pegram MD
Cancer Med; 2019 Apr; 8(4):1755-1764. PubMed ID: 30848103
[TBL] [Abstract] [Full Text] [Related]
14. Core needle biopsy as an alternative to whole section in ihc4 score assessment for breast cancer prognostication.
Liu M; Tang SX; Tsang JYS; Shi YJ; Ni YB; Law BKB; Tse GMK
J Clin Pathol; 2018 Dec; 71(12):1084-1089. PubMed ID: 30228212
[TBL] [Abstract] [Full Text] [Related]
15. Novel 18-gene signature for predicting relapse in ER-positive, HER2-negative breast cancer.
Buus R; Yeo B; Brentnall AR; Klintman M; Cheang MCU; Khabra K; Sestak I; Gao Q; Cuzick J; Dowsett M
Breast Cancer Res; 2018 Sep; 20(1):103. PubMed ID: 30180877
[TBL] [Abstract] [Full Text] [Related]
16. Value of Information Analysis of Multiparameter Tests for Chemotherapy in Early breast cancer: The OPTIMA Prelim Trial.
Hall PS; Smith A; Hulme C; Vargas-Palacios A; Makris A; Hughes-Davies L; Dunn JA; Bartlett JMS; Cameron DA; Marshall A; Campbell A; Macpherson IR; Dan Rea ; Francis A; Earl H; Morgan A; Stein RC; McCabe C;
Value Health; 2017 Dec; 20(10):1311-1318. PubMed ID: 29241890
[TBL] [Abstract] [Full Text] [Related]
17. Evaluation of applying ihc4 as a prognostic model in the translational study of Intergroup Exemestane Study (IES): PathIES.
Cheang MCU; Bliss JM; Viale G; Speirs V; Palmieri C; Shaaban A; Lønning PE; Morden J; Porta N; Jassem J; van De Velde CJ; Rasmussen BB; Verhoeven D; Bartlett JMS; Coombes RC;
Breast Cancer Res Treat; 2018 Feb; 168(1):169-178. PubMed ID: 29177605
[TBL] [Abstract] [Full Text] [Related]
18. Relevance of Spatial Heterogeneity of Immune Infiltration for Predicting Risk of Recurrence After Endocrine Therapy of ER+ breast cancer.
Heindl A; Sestak I; Naidoo K; Cuzick J; Dowsett M; Yuan Y
J Natl Cancer Inst; 2018 Feb; 110(2):. PubMed ID: 28859291
[TBL] [Abstract] [Full Text] [Related]
19. Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial.
Nitz U; Gluz O; Christgen M; Kates RE; Clemens M; Malter W; Nuding B; Aktas B; Kuemmel S; Reimer T; Stefek A; Lorenz-Salehi F; Krabisch P; Just M; Augustin D; Liedtke C; Chao C; Shak S; Wuerstlein R; Kreipe HH; Harbeck N
Breast Cancer Res Treat; 2017 Oct; 165(3):573-583. PubMed ID: 28664507
[TBL] [Abstract] [Full Text] [Related]
20. GENE EXPRESSION PROFILING AND EXPANDED IMMUNOHISTOCHEMISTRY TESTS TO GUIDE SELECTION OF CHEMOTHERAPY REGIMENS IN breast cancer MANAGEMENT: A SYSTEMATIC REVIEW.
Scope A; Essat M; Pandor A; Rafia R; Ward SE; Wyld L; Cross S; Woods HB
Int J Technol Assess Health Care; 2017 Jan; 33(1):32-45. PubMed ID: 28486999
[TBL] [Abstract] [Full Text] [Related]
[Next]
